Grace Therapeutics (GRCE) Expected to Post Quarterly Earnings on Thursday

Grace Therapeutics (NASDAQ:GRCE) is projected to release its Q2 2027 results before the market opens on Thursday, November 12th. Analysts expect Grace Therapeutics to announce earnings of ($0.15) per share and revenue of $1.00 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2027 earnings report page for the latest details on the call scheduled for Friday, November 20, 2026 at 9:30 AM ET.

Grace Therapeutics (NASDAQ:GRCE) last announced its earnings results on Friday, August 14th. The company reported ($0.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.78). During the same quarter in the prior year, the business posted ($0.21) earnings per share.

Grace Therapeutics Stock Down 0.3%

Grace Therapeutics stock opened at $1.86 on Wednesday. The stock has a 50-day simple moving average of $2.03 and a 200 day simple moving average of $2.77. Grace Therapeutics has a 12-month low of $1.67 and a 12-month high of $5.18. The stock has a market capitalization of $39.13 million, a price-to-earnings ratio of -1.58 and a beta of 0.43.

Analyst Upgrades and Downgrades

GRCE has been the subject of several research reports. Zacks Research upgraded shares of Grace Therapeutics to a “hold” rating in a research report on Monday, August 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Grace Therapeutics in a research note on Thursday, October 15th. Finally, Wall Street Zen lowered shares of Grace Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $6.00.

About Grace Therapeutics

Grace Therapeutics, Inc. (NASDAQ: GRCE) is a clinical-stage biopharmaceutical company developing therapies for rare and life-threatening medical conditions. The company focuses on drug-delivery technologies intended to improve the administration, absorption, and therapeutic performance of established pharmaceutical compounds. Grace Therapeutics’ lead candidate is GTx-104, an investigational injectable formulation of nimodipine being developed for patients with aneurysmal subarachnoid hemorrhage, a serious form of bleeding around the brain.